Vitamin K to prevent fractures in older women: systematic review and economic evaluation
Open accessThe DOI matches its Crossref record; 264 of the 275 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine the clinical and cost-effectiveness of vitamin K in preventing osteoporotic fractures in postmenopausal women. DATA SOURCES: Searches were conducted in May 2007 in MEDLINE, MEDLINE In-Process, EMBASE, Cochrane Database of Systematic Reviews, Cochrane Controlled Trials Register, BIOSIS, CINAHL, DARE, NHS EED and HTA databases, AMED, NRR, Science Citation Index and Current Controlled Trials. The MEDLINE search was updated in March 2009. REVIEW METHODS: Selected studies were assessed and subjected to data extraction and quality assessment using standard methods. Where appropriate, meta-analysis was carried out. A mathematical model was constructed to estimate the cost-effectiveness of vitamin K1. RESULTS: The electronic literature searches identified 1078 potentially relevant articles. Of these, 14 articles relating to five trials that compared vitamin K with a relevant comparator in postmenopausal women with osteoporosis or osteopenia met the review inclusion criteria. The double-blind ECKO trial compared 5 mg of phylloquinone (vitamin K1) with placebo in Canadian women with osteopenia but without osteoporosis. Four open-label trials used 45 mg of menatetrenone (vitamin K2) in Japanese women with osteoporosis; the comparators were no treatment, etidronate or calcium. The methodological quality of the ECKO trial was good; however, all four menatetrenone trials were poorly reported and three were very small (n < 100 in each group). Phylloquinone was associated with a statistically significant reduction in the risk of clinical fractures relative to placebo [relative risk 0.46, 95% confidence interval (CI) 0.22 to 0.99]; morphometric vertebral fractures were not reported. The smaller menatetrenone trials found that menatetrenone was associated with a reduced risk of morphometric vertebral fractures relative to no treatment or calcium; however, the larger Osteoporosis Fracture (OF) study found no evidence of a reduction in vertebral fracture risk. The three smaller trials found no significant difference between treatment groups in non-vertebral fracture incidence. In the ECKO trial, phylloquinone was not associated with an increase in adverse events. In the menatetrenone trials, adverse event reporting was generally poor; however, in the OF study, menatetrenone was associated with a significantly higher incidence of skin and skin appendage lesions. No published economic evaluations of vitamin K were found and a mathematical model was thus constructed to estimate the cost-effectiveness of vitamin K1. Comparators were alendronate, risedronate and strontium ranelate. Vitamin K1 and alendronate were markedly more cost-effective than either risedronate or strontium ranelate. The base-case results favoured vitamin K1, but this relied on many assumptions, particularly on the efficacy of preventing hip and vertebral fractures. Calculation of the expected value of sampled information was conducted assuming a randomised controlled trial of 5 years' duration comparing alendronate with vitamin K1. The costs incurred in obtaining updated efficacy data from a trial with 2000 women per arm were estimated to be a cost-effective use of resources. CONCLUSIONS: There is currently large uncertainty over whether vitamin K1 is more cost-effective than alendronate; further research is required. It is unlikely that the present prescribing policy (i.e. alendronate as first-line treatment) would be altered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are insufficient data for hip fracture outcomes from trials of alphacalcidiol, 26 B 12 /folate, or vitamin K by other investigators, but vitamin K is reported to have no effect on bone density 29 or vertebral fracture risk.30”
From Systematic review and statistical analysis of the integrity of 33 randomized controlled trials (2016) · cites this paper as [30]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Part of this paper’s reference list could not be split into single entries.
1 retracted
Items 201–264 of 264
Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment
Hyde, C., Wake, B., Bryan, S., Barton, P., Fry-Smith, A., Davenport, C., & Song, F. (2002) · Health Technology Assessment · doi:10.3310/hta6020 · Cited by 90
Hosking, D., Adami, S., Felsenberg, D., Andia, J. C., Välimäki, M., Benhamou, L., Reginster, J.-Y., Yacik, C., Rybak-Feglin, A., Petruschke, R. A., et al. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125002009 · Cited by 89
Elliott, R. A., Payne, K., Moore, J. K., Davies, L. M., Harper, N. J. N., St. Leger, A. S., Moore, E. W., Thoms, G. M. M., Pollard, B. J., McHugh, G. A., et al. (2002) · Health Technology Assessment · doi:10.3310/hta6300 · Cited by 89
Bagnall, A., Jones, L., Richardson, G., Duffy, S., & Riemsma, R. (2003) · Health Technology Assessment · doi:10.3310/hta7190 · Cited by 86
Ste‐Marie, L., Sod, E. W., Johnson, T. D., & Chines, A. A. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0039-7 · Cited by 82
Jones, L., Hawkins, N., Westwood, M., Wright, K., Richardson, G., & Riemsma, R. (2004) · Health Technology Assessment · doi:10.3310/hta8050 · Cited by 81
Iwamoto, I., Kosha, S., Noguchi, S., Murakami, M., Fujino, T., Douchi, T., & Nagata, Y. (1999) · Maturitas · doi:10.1016/s0378-5122(98)00114-5 · Cited by 81
Stevenson, M. D., Oakley, J., & Chilcott, J. B. (2004) · Medical Decision Making · doi:10.1177/0272989x03261561 · Cited by 81
Self-citationIwamoto, J., Takeda, T., & Ichimura, S. (2001) · Journal of Orthopaedic Science · doi:10.1007/s007760100002 · Cited by 80
Cost-effectiveness of Fracture Prevention in Established Osteoporosis
Jönsson, B., Christiansen, C., Johnell, O., Hedbrandt, J., & Karlsson, G. (1996) · Scandinavian Journal of Rheumatology · doi:10.3109/03009749609103742 · Cited by 80
C.W.*, T., Paul, A. A., Bates, C. J., Bolton-Smith, C., Prentice, A., & Shearer, M. J. (2002) · British Journal Of Nutrition · doi:10.1079/bjnbjn2002583 · Cited by 80
Cosby, K. (2017) · Diagnosis · doi:10.1201/9781315116334-2 · Cited by 80
Cost-effectiveness of fracture prevention in established osteoporosis
Jönsson, B., Christiansen, C., Johnell, O., & Hedbrandt, J. (1995) · Osteoporosis International · doi:10.1007/bf01623315 · Cited by 79
McDonagh, Bachmann, Golder, Kleijnen, & ter Riet (2000) · Health Technology Assessment · doi:10.3310/hta4300 · Cited by 79
Autoantibody testing in children with newly diagnosed type 1 diabetes mellitus
Dretzke, J., Cummins, C., Sandercock, J., Fry-Smith, A., Barrett, T., & Burls, A. (2004) · Health Technology Assessment · doi:10.3310/hta8220 · Cited by 77
Ten Years’ Experience With Alendronate for Osteoporosis in Postmenopausal Women
Bone, H. G., Hosking, D. J., Devogelaer, J., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., et al. (2004) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000134304.25332.ef · Cited by 76
Clemmesen, B., Ravn, P., Zegels, B., Taquet, A. N., Christiansen, C., & Reginster, J.-Y. (1997) · Osteoporosis International · doi:10.1007/pl00004152 · Cited by 76
Gillespie, W., Avenell, A., Henry, D., O'Connell, D., & Robertson, J. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000227 · Cited by 75
Infliximab for the treatment of adults with psoriasis
Loveman, E., Turner, D., Hartwell, D., Cooper, K., & Clegg, A. J. (2009) · Health Technology Assessment · doi:10.3310/hta13suppl1/09 · Cited by 73
Holt, G., Khaw, K.-T., Reid, D. M., Compston, J. E., Bhalla, A., Woolf, A. D., Crabtree, N. J., Dalzell, N., Wardley‐Smith, B., Lunt, M., et al. (2002) · British Journal of Radiology · doi:10.1259/bjr.75.897.750736 · Cited by 69
Rituximab for the treatment of rheumatoid arthritis
Bagust, A., Boland, A., Hockenhull, J., Fleeman, N., Greenhalgh, J., Dundar, Y., Proudlove, C., Kennedy, T. M., Moots, R. J., Williamson, P. R., et al. (2009) · Health Technology Assessment · doi:10.3310/hta13suppl2/04 · Cited by 67
Efficient computation of partial expected value of sample information using Bayesian approximation
Brennan, A., & Kharroubi, S. A. (2006) · Journal of Health Economics · doi:10.1016/j.jhealeco.2006.06.002 · Cited by 65
Holmes, M., Carroll, C., & Papaioannou, D. E. (2009) · Health Technology Assessment · doi:10.3310/hta13suppl2/08 · Cited by 65
Self-citationVitamin K in the treatment and prevention of osteoporosis and arterial calcification
Adams, J. P., & Pepping, J. (2005) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp040357 · Cited by 64
Pleiotropic actions of vitamin K: protector of bone health and beyond?
Kaneki, M., Hosoi, T., Ouchi, Y., & Orimo, H. (2006) · Nutrition · doi:10.1016/j.nut.2006.05.003 · Cited by 61
Marquis, P., Roux, C., de la Loge, C., Díaz Curiel, M., Cormier, C., Isaia, G. C., Badurski, J. E., Wark, J. D., & Meunier, P. J. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0464-3 · Cited by 57
Effect of partial compliance on cardiovascular medication effectiveness
Cramer, J. A. (2002) · Heart · doi:10.1136/heart.88.2.203 · Cited by 57
Griffin, S. C., Walker, S., Sculpher, M. J., White, S., Erhorn, S., Brent, S., Dyker, A. G., Ferrie, L., Gilfillan, C., Horsley, W. H., et al. (2009) · Health Technology Assessment · doi:10.3310/hta13suppl1/08 · Cited by 55
COMPARISON OF ALENDRONATE, CALCITONIN AND CALCIUM TREATMENTS IN POSTMENOPAUSAL OSTEOPOROSIS
Dursun, N., Dursun, E., & Yalçin, S. (2001) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2001.tb11111.x · Cited by 53
Adalimumab for the treatment of psoriasis
Turner, D., Picot, J., Cooper, K., & Loveman, E. (2009) · Health Technology Assessment · doi:10.3310/hta13suppl2/07 · Cited by 53
Schaafsma, A., Muskiet, F., Storm, H., Hofstede, G., Pakan, I., & van der Veer, E. (2000) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1601065 · Cited by 52
Chilcott, J. B., Jones, M. L., & Wilkinson, A. (2009) · Health Technology Assessment · doi:10.3310/hta13suppl1/02 · Cited by 50
Bortezomib for the treatment of multiple myeloma patients
Green, C., Bryant, J., Takeda, A., Cooper, K., Clegg, A. J., Smith, A. J., & Stephens, M. (2009) · Health Technology Assessment · doi:10.3310/hta13suppl1/05 · Cited by 49
Meunier, P. J., & Reginster, J.-Y. (2003) · Osteoporosis International · doi:10.1007/s00198-002-1341-8 · Cited by 47
Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia
Walker, S., Palmer, S., Erhorn, S., Brent, S., Dyker, A. G., Ferrie, L., Horsley, W. H., Macfarlane, K. W., White, S., & Thomas, S. (2009) · Health Technology Assessment · doi:10.3310/hta13suppl1/06 · Cited by 47
Boland, A., Bagust, A., Hockenhull, J., Davis, H. E., Chu, P., & Dickson, R. (2009) · Health Technology Assessment · doi:10.3310/hta13suppl2/06 · Cited by 46
Omalizumab for the treatment of severe persistent allergic asthma
Jones, J., Shepherd, J., Hartwell, D., Harris, P., Cooper, K., Takeda, A., & Davidson, P. (2009) · Health Technology Assessment · doi:10.3310/hta13suppl2-05 · Cited by 46
Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin’s lymphoma
Dundar, Y., Bagust, A., Hounsome, J. C., McLeod, C., Boland, A., Davis, H. E., Walley, T., & Dickson, R. (2009) · Health Technology Assessment · doi:10.3310/hta13suppl1/04 · Cited by 44
The hospitalisation costs and out-patient costs of fragility fractures
Stevenson, M., Davis, S., & Kanis, J. (2006) · Women s Health Medicine · doi:10.1383/wohm.2006.3.4.149 · Cited by 44
Self-citationBond, M., Hoyle, M., Moxham, T., Napier, M., & Anderson, R. (2009) · Health Technology Assessment · doi:10.3310/hta13suppl2/10 · Cited by 44
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws
THIERS, B. H. (2007) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70544-6 · Cited by 43
Erlotinib for the treatment of relapsed non-small cell lung cancer
McLeod, C., Bagust, A., Boland, A., Hockenhull, J., Dundar, Y., Proudlove, C., Davis, H. E., Green, J., Macbeth, F. R., Stevenson, J., et al. (2009) · Health Technology Assessment · doi:10.3310/hta13suppl1/07 · Cited by 41
Steinbuch, M., D’Agostino, R. B., Mandel, J. S., Gabrielson, E., McClung, M. R., Stemhagen, A., & Hofman, A. (2002) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2002.1550 · Cited by 39
Effect of Dietary Fat Content on Oral Bioavailability of Menatetrenone in Humans
Uematsu, T., Nagashima, S., Niwa, M., Kohno, K., Sassa, T., Ishii, M., Tomono, Y., Yamato, C., & Kanamaru, M. (1996) · Journal of Pharmaceutical Sciences · doi:10.1021/js9600641 · Cited by 39
The epidemiology of osteoporosis
Evans, J. G. (1993) · Reviews in Clinical Gerontology · doi:10.1017/s0959259800003245 · Cited by 39
The use of paclitaxel in the management of early stage breast cancer
Griffin, S. C., Dunn, G., Palmér, S., Macfarlane, K. W., Brent, S., Dyker, A. G., Erhorn, S., Humphries, C., White, S., Horsley, W. H., et al. (2009) · Health Technology Assessment · doi:10.3310/hta13suppl1/03 · Cited by 38
Vitamin K2 treatment for postmenopausal osteoporosis in Indonesia
Purwosunu, Y., Muharram, Rachman, I. A., Reksoprodjo, S., & Sekizawa, A. (2006) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2006.00386.x · Cited by 37
Varenicline in the management of smoking cessation: a single technology appraisal
Hind, D., Tappenden, P., Peters, J., & Kenjegalieva, K. (2009) · Health Technology Assessment · doi:10.3310/hta13suppl2/02 · Cited by 35
Health care costs of women with symptomatic vertebral fractures
Puffer, S., Torgerson, D. J., Sykes, D., Brown, P., & Cooper, C. C. (2004) · Bone · doi:10.1016/j.bone.2004.03.035 · Cited by 35
Asakura, H., Myou, S., Ontachi, Y., Kato, M., Saito, M., Yamazaki, M., Nakao, S., Mizutani, T., & Morishita, E. (2001) · Osteoporosis International · doi:10.1007/s001980170007 · Cited by 34
Mowatt, G., Boachie, C., Crowther, M. A., Fraser, C. M., Hernández, R. A., Jia, X., & Ternent, L. (2009) · Health Technology Assessment · doi:10.3310/hta13suppl2/09 · Cited by 33
Stevenson, M., Oakley, J. E., Jones, M. L., Brennan, A., Compston, J. E., McCloskey, E. V., & Selby, P. L. (2009) · Medical Decision Making · doi:10.1177/0272989x09336077 · Cited by 32
Self-citationAlteplase for the treatment of acute ischaemic stroke: a single technology appraisal
Jones, M. L., & Holmes, M. (2009) · Health Technology Assessment · doi:10.3310/hta13suppl2/03 · Cited by 30
Ten years’ experience with alendronate for osteoporosis in postmenopausal women*
(2004) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000132849.06696.4b · Cited by 30
Stevenson, M., Brazier, J. E., Calvert, N., Lloyd-Jones, M., Oakley, J. E., & Kanis, J. А. (2004) · Journal of the Operational Research Society · doi:10.1057/palgrave.jors.2601903 · Cited by 29
Self-citationVoss, S., Quail, D., Dawson, A., Bäckström, T., Águas, F., Erenus, M., Thé, H. S., Bonnar, J., Geyter, C. D., Hunter, M. S., et al. (2002) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2002.01510.x · Cited by 29
Vitamin K status in the elderly
Booth, S. L. (2006) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e328011ab5f · Cited by 27
Buist, D. S. M., LaCroix, A. Z., Black, D. M., Harris, F., Blank, J., Ensrud, K. E., Edgerton, D., Rubin, S., & Fox, K. M. (2000) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb04790.x · Cited by 24
Calcium, Vitamin D and Vitamin K in the Prevention of Fractures due to Osteoporosis
Meunier, P. J. (1999) · Osteoporosis International · doi:10.1007/pl00004161 · Cited by 23
The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis
Ding, H., Koinuma, N., Stevenson, M., Ito, M., & Monma, Y. (2007) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-007-0794-4 · Cited by 22
Self-citationStrontium ranelate: short- and long-term benefits for post-menopausal women with osteoporosis
Roux, C. (2008) · Lara D. Veeken · doi:10.1093/rheumatology/ken166 · Cited by 20
Hip fracture incidence in Japan
Orimo, H., Hosoda, Y., Fujiwara, S., Mizuno, S., Hashimoto, T., Tamaki, T., Nose, T., Yamamoto, K., & Sasaki, R. (1991) · Journal of Bone and Mineral Metabolism · doi:10.1007/bf02375926 · Cited by 19
Lewis, R. A., Bagnall, A., King, S., Woolacott, N. F., Forbes, C. A., Shirran, L., Duffy, S., Kleijnen, J., ter Riet, G., & Riemsma, R. P. (2002) · Health Technology Assessment · doi:10.3310/hta6140 · Cited by 15
Calcium and vitamin D in preventing fractures: Vitamin K supplementation has powerful effect
Radecki, T. E. (2005) · BMJ · doi:10.1136/bmj.331.7508.108 · Cited by 6
Research works printed but not linked: 15
- Torgerson DJ, Dolan P. The cost of treating osteoporotic fractures in the United Kingdom female population -the author replies. Osteoporos Int 2000;11:551-2.
- Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delams P, et al. Predictive value of bone mineral density for hip and other fractures. J Bone Miner Res 2005;20:1185-94.
- Duggan P, Cashman KD, Flynn A, Bolton-Smith C, Kiely M. Phylloquinone (vitamin K-1) intakes and food sources in 18-year-old to 64-year-old Irish adults. Br J Nutr 2004;92:151-8.
- Compston JE. Boning up on vitamin K - commentary. Gut 2001;48:448.
- Fairfield KM, Fletcher RH. Vitamins for chronic disease prevention in adults: scientific review [erratum appears in JAMA 2002;288:1720]. JAMA 2002;287:3116-26.
- Cambridge Laboratories. Menadiol diphosphate tablets 10mg. 2002. URL: http://emc.medicines.org.uk/.
- National Osteoporosis Foundation Working Group on Vertebral Fractures. Assessing vertebral fractures. J Bone Miner Res 1995;10:518-523.
- Genant HK, Jergas M. Assessment of prevalent and incident fractures in osteoporosis research. Osteoporos Int 2003;14:S43-S55.
- Cranney A, Tugwell P, Wells G, Guyatt G. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev 2002;23:497-507.
- Insull W, Troendle A, Silvers A, Dunne CW. Substantial non-compliance to dose and time prescriptions for medications treating hypercholesterolaemia. Atherosclerosis 1995;115:S93.
- Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. Is this patient taking the treatment as prescribed? JAMA 1993;269:2779-81.
- Howell N, Trotter R, Mottram DR, Rowe PH. Compliance with statins in primary care. Pharm J 2004;272:23-6.
- Cochrane Review Manager 4.2.7. Oxford: The Cochrane Collaboration; 2004. URL: http://ims. cochrane.org/revman/.
- Shiraki M. Vitamin K2 effects on the risk of fractures and on lumbar bone mineral density in osteoporosis -a randomized prospective open-label 3-year study. Osteoporos Int 2002;13:S160.
- Eisai Co. Ltd. Eisai announces the intermediate analysis of anti-osteoporosis treatment post-marketing research to investigate the benefits of menatetrenone as part of the Ministry of Health, Labour and Welfare's Pharmacoepidemiological Drug Review Program. 2005. URL: www.eisai.co.jp/enews/.
Cited by
Fihn, S. D., Blankenship, J. C., Alexander, K. P., Bittl, J. A., Byrne, J. G., Fletcher, B. J., Fonarow, G. C., Lange, R. A., Levine, G. N., Maddox, T. M., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000095 · Cited by 1,029
Gribble, P. A., Bleakley, C. M., Caulfield, B. M., Docherty, C. L., Fourchet, F., Fong, D. T.-P., Hertel, J., Hiller, C. E., Kaminski, T. W., McKeon, P. O., et al. (2016) · British Journal of Sports Medicine · doi:10.1136/bjsports-2016-096189 · Cited by 690
Doherty, C., Bleakley, C., Delahunt, E., & Holden, S. (2017) · British Journal of Sports Medicine · doi:10.1136/bjsports-2016-096178 · Cited by 408
Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis
Tan, D. H. S., Hull, M. W., Yoong, D., Tremblay, C., O’Byrne, P., Thomas, R., Kille, J., Baril, J.-G., Cox, J., Giguere, P., et al. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.170494 · Cited by 220
O'Doherty, L. J., Taft, A., Hegarty, K., Ramsay, J., Davidson, L. L., & Feder, G. (2014) · BMJ · doi:10.1136/bmj.g2913 · Cited by 202
Metadata
- Authors
- Stevenson, M., Lloyd-Jones, M., & Papaioannou, D.
- Affiliations
- University of Southampton (GB)
- Corresponding author
- Stevenson, M
- Venue
- Health Technology Assessment
- Published
- 2009-09
- Volume
- 13
- Issue
- 45
- Pages
- iii-xi, 1
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2158674987
- Cited by
- 90
- References
- 275
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 1 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 6 · 2017: 5 · 2016: 15 · 2015: 6 · 2014: 18 · 2013: 8 · 2012: 9
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Health Technology Assessment (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Health Technology Assessment programme (07/16/01)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Vitamin K Research Studies
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Vitamin D Research Studies
- Keywords
- vitamin K, osteoporotic fractures, postmenopausal women, vitamin K1, menatetrenone, fracture prevention, cost-effectiveness, vertebral fractures, non-vertebral fractures, osteopenia, osteoporosis, adverse events, economic evaluation model
- MeSH terms
- Aged, Aged, 80 and over, Cost-Benefit Analysis, Female, Humans, Vitamin K 1, Vitamin K, Vitamins, Osteoporosis, Postmenopausal, Models, Econometric, Quality-Adjusted Life Years, Vitamin K 2, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.